急性髓系白血病患者血清可溶性E钙粘蛋白、可溶性白细胞介素-2受体水平与疗效及预后的关系  

Relationship between serum levels of soluble E cadherin and soluble interleukin-2 receptor and efficacy and prognosis in patients with acute myeloid leukemia

作　　者：吴志敏[1] 魏秀丽[1] 郭莉[1] 王继芳[1] 李林霞 Wu Zhimin;Wei Xiuli;Guo Li;Wang Jifang;Li Linxia(Department of hematology,Xinxiang first people's hospital,Xinxiang,Henan,453000,China)

机构地区：[1]新乡市第一人民医院血液内科,河南新乡453000

出　　处：《齐齐哈尔医学院学报》2021年第20期1761-1764,共4页Journal of Qiqihar Medical University

摘　　要：目的研究急性髓系白血病(AML)患者血清可溶性E钙粘蛋白(SE-CAD)、可溶性白细胞介素-2受体(sCD25)水平与疗效及预后的关系。方法选择2018年1月—2019年10月本院收治的62例AML患者作为研究对象,按照临床分期的不同分为初治组(20例)、缓解组(23例)和复发组(19例)三组。采用酶联免疫吸附法检测三组血清SE-CAD、sCD25水平并进行对比。此外,将所有受试者按照存活状态的不同分为死亡组(17例)和存活组(45例)两组,分析两组血清SE-CAD、sCD25水平以及各项基线资料的差异。通过多因素Logistic回归分析明确AML患者预后与各项影响因素的关系。结果缓解组血清SE-CAD、sCD25水平分别为(2.24±0.46)ng/ml、(2613.45±311.84)pg/ml,均明显低于初治组的(7.71±1.15)ng/ml、(4237.94±653.62)pg/ml以及复发组的(8.14±1.23)ng/ml、(4310.55±641.39)pg/ml,差异均有统计学意义(均P<0.05)。死亡组的血清SE-CAD、sCD25水平分别为(8.52±0.85)ng/ml、(5013.82±746.87)pg/ml,均明显高于存活组的(4.01±0.57)ng/ml、(3140.49±459.38)pg/ml,差异有统计学意义(P<0.05)。死亡组年龄、PS评分、脏器并发症以及初治时的白细胞计数与存活组比较差异明显(P<0.05)。经多因素Logistic回归分析发现:年龄、PS评分、脏器并发症、初治时的白细胞计数以及血清SE-CAD、sCD25水平均是AML患者死亡的危险因素(OR>1,P<0.05)。结论血清SE-CAD、sCD25可能作为临床辅助评价AML患者治疗疗效以及预后的血清学指标。Objective To study the relationship between serum levels of soluble E cadherin(SE-CAD)and soluble interleukin-2 receptor(sCD25)and efficacy and prognosis in patients with acute myeloid leukemia(AML).Methods 62 patients with AML those were admitted to Xinxiang first people's hospital from January 2018 to October 2019 were included in the study.According to the clinical stages,they were divided into the initial treatment group(20 cases),the remission group(23 cases)and the recurrence group(19 cases).The levels of serum SE-CAD and sCD25 in the three groups were detected by enzyme-linked immunosorbent assayand the results were compared.In addition,all subjects were divided into the death group(17 cases)and the survival group(45 cases)according to their survival status,and the differences of serum levels of SE-CAD and sCD25 and baseline data were analyzed.Multivariate Logistic regression analysis was used to determine the relationship between the prognosis and various influencing factors of patients with AML.Results Serum levels of SE-CAD and sCD25 in the remission group were(2.24±0.46)ng/ml and(2613.45±311.84)pg/ml respectively,which were significantly lower than(7.71±1.15)ng/ml and(4237.94±653.62)pg/ml in the initial treatment group,and(8.14±1.23)ng/ml and(4310.55±641.39)pg/ml in the recurrence group,respectively,with statistically significant differences(all P<0.05).The serum levels of SE-CAD and sCD25 in the death group were(8.52±0.85)ng/ml and(5013.82±746.87)pg/ml,respectively,which were significantly higher than(4.01±0.57)ng/ml and(3140.49±459.38)pg/ml in survival group,respectively,with statistically significant differences(P<0.05).There were significant differences in age,PS score,viscera complications and white blood cell count at initial treatment between the death group and the survival group(P<0.05).Multiple Logistic regression analysis showed that age,PS score,visceral complications,white blood cell count at initial treatment,serum levels of SE-CAD and sCD25 were all risk factors for death of pa

关 键 词：急性髓系白血病 可溶性E钙粘蛋白 可溶性白细胞介素-2受体 疗效 预后 

分 类 号：R733.7[医药卫生—肿瘤]